DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Buy, Sell Or Hold: Zydus Lifesciences, Cyient, BEL, Shriram Finance, IOB, Avanti Feeds — Ask Profit

NDTV Profit 2 hrs ago·26 Oct 2026, 7:17 pm

Ask Profit recently released a research note that included Zydus Lifesciences among a group of stocks it reviewed. The note looked at the company's latest financial results, product pipeline and its position in the Indian pharmaceutical market.

For investors, the analysis is relevant because Zydus Lifesciences operates in a sector that is sensitive to regulatory approvals, pricing pressures and demand for generic and specialty medicines. The company's ability to launch new products and manage costs can influence its revenue growth and profit margins.

Going forward, market participants will likely keep an eye on the upcoming quarterly earnings, any new drug approvals or launches, and broader policy changes affecting pharma pricing. Trends in domestic consumption and export demand could also shape the stock's performance in the near term.